Home > Insider Trading > Latest 13D and 13G Filings > 13G Filing (0001104659-21-022598)

Filing Details

Accession Number:: 0001104659-21-022598
Form Type:: 13G Filing
Publication Date:: 2021-02-16 06:28:44

Filed By:: 5am Ventures Iv, L.p.
Company:: Q32 Bio Inc. (NASDAQ:QTTB)
Filing Date:: 2021-02-16
SEC Url:: 13G Filing

Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name	Shared Voting Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
5AM Ventures IV	4,354,484	4,354,484	4,354,484	9.6%
5AM Co-Investors IV	181,435	181,435	181,435	0.4%
5AM Partners IV	4,535,919	4,535,919	4,535,919	10.0%
Dr. John D. Diekman	4,535,919	4,535,919	4,535,919	10.0%
Andrew J. Schwab	4,535,919	4,535,919	4,535,919	10.0%
Dr. Scott M. Rocklage	4,535,919	4,535,919	4,535,919	10.0%

Filing


	UNITED STATES
	SECURITIES AND EXCHANGE COMMISSION
	Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 2)*

Homology Medicines, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

438083107

(CUSIP Number)

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o	Rule 13d-1(b)
o	Rule 13d-1(c)
x	Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 438083107

	1.	Names of Reporting Persons 5AM Ventures IV, L.P.

	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x (1)

	3.	SEC Use Only

	4.	Citizenship or Place of Organization Delaware, United States of America

Number of Shares Beneficially Owned by Each Reporting Person With			5.		Sole Voting Power 0 shares

			6.		Shared Voting Power 4,354,484 shares (2)

			7.		Sole Dispositive Power 0 shares

			8.		Shared Dispositive Power 4,354,484 shares (2)

	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,354,484 shares (2)

	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o

	11.	Percent of Class Represented by Amount in Row (9) 9.6% (3)

	12.	Type of Reporting Person (See Instructions) PN

(1) This Schedule 13G is filed by 5AM Ventures IV, L.P., a Delaware limited partnership (Ventures IV), 5AM Co-Investors IV, L.P., a Delaware limited partnership (Co-Investors IV), 5AM Partners IV, LLC, a Delaware limited liability company (Partners IV), Dr. John D. Diekman (Diekman), Andrew J. Schwab (Schwab), and Dr. Scott M. Rocklage (Rocklage and together with Ventures IV, Co-Investors IV, Partners IV, Diekman and Schwab, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Partners IV serves as the sole general partner of Ventures IV. Diekman, Schwab and Rocklage are managing members of Partners IV and share voting and dispositive power over the shares held by Ventures IV. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2020.

(3) This percentage is calculated based upon 45,264,419 shares of Common Stock outstanding as of November 2, 2020 as indicated in the Issuers Form 10-Q filed on November 9, 2020.

CUSIP No. 438083107

	1.	Names of Reporting Persons 5AM Co-Investors IV, L.P.

	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x (1)

	3.	SEC Use Only

	4.	Citizenship or Place of Organization Delaware, United States of America

Number of Shares Beneficially Owned by Each Reporting Person With			5.		Sole Voting Power 0 shares

			6.		Shared Voting Power 181,435 shares (2)

			7.		Sole Dispositive Power 0 shares

			8.		Shared Dispositive Power 181,435 shares (2)

	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 181,435 shares (2)

	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o

	11.	Percent of Class Represented by Amount in Row (9) 0.4% (3)

	12.	Type of Reporting Person (See Instructions) PN

(1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Partners IV serves as the sole general partner of Co-Investors IV. Diekman, Schwab and Rocklage are managing members of Partners IV and share voting and dispositive power over the shares held by Co-Investors IV. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2020.

(3) This percentage is calculated based upon 45,264,419 shares of Common Stock outstanding as of November 2, 2020 as indicated in the Issuers Form 10-Q filed on November 9, 2020.

CUSIP No. 438083107

	1.	Names of Reporting Persons 5AM Partners IV, LLC

	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x (1)

	3.	SEC Use Only

	4.	Citizenship or Place of Organization Delaware, United States of America

Number of Shares Beneficially Owned by Each Reporting Person With			5.		Sole Voting Power 0 shares

			6.		Shared Voting Power 4,535,919 shares (2)

			7.		Sole Dispositive Power 0 shares

			8.		Shared Dispositive Power 4,535,919 shares (2)

	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,535,919 shares (2)

	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o

	11.	Percent of Class Represented by Amount in Row (9) 10.0% (3)

	12.	Type of Reporting Person (See Instructions) OO

(1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Includes 4,354,484 shares of Common Stock held by Ventures IV and 181,435 shares of Common Stock held by Co-Investors IV. Partners IV serves as the sole general partner of Ventures IV and Co-Investors IV. Diekman, Schwab and Rocklage are managing members of Partners IV and share voting and dispositive power over the shares held by Ventures IV and Co-Investors IV. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2020.

(3) This percentage is calculated based upon 45,264,419 shares of Common Stock outstanding as of November 2, 2020 as indicated in the Issuers Form 10-Q filed on November 9, 2020.

CUSIP No. 438083107

	1.	Names of Reporting Persons Dr. John D. Diekman

	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x (1)

	3.	SEC Use Only

	4.	Citizenship or Place of Organization United States of America

Number of Shares Beneficially Owned by Each Reporting Person With			5.		Sole Voting Power 0 shares

			6.		Shared Voting Power 4,535,919 shares (2)

			7.		Sole Dispositive Power 0 shares

			8.		Shared Dispositive Power 4,535,919 shares (2)

	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,535,919 shares (2)

	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o

	11.	Percent of Class Represented by Amount in Row (9) 10.0% (3)

	12.	Type of Reporting Person (See Instructions) IN

(1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(3) This percentage is calculated based upon 45,264,419 shares of Common Stock outstanding as of November 2, 2020 as indicated in the Issuers Form 10-Q filed on November 9, 2020.

CUSIP No. 438083107

	1.	Names of Reporting Persons Andrew J. Schwab

	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x (1)

	3.	SEC Use Only

	4.	Citizenship or Place of Organization United States of America

Number of Shares Beneficially Owned by Each Reporting Person With			5.		Sole Voting Power 0 shares

			6.		Shared Voting Power 4,535,919 shares (2)

			7.		Sole Dispositive Power 0 shares

			8.		Shared Dispositive Power 4,535,919 shares (2)

	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,535,919 shares (2)

	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o

	11.	Percent of Class Represented by Amount in Row (9) 10.0% (3)

	12.	Type of Reporting Person (See Instructions) IN

(1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(3) This percentage is calculated based upon 45,264,419 shares of Common Stock outstanding as of November 2, 2020 as indicated in the Issuers Form 10-Q filed on November 9, 2020.

CUSIP No. 438083107

	1.	Names of Reporting Persons Dr. Scott M. Rocklage

	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		o
		(b)		x (1)

	3.	SEC Use Only

	4.	Citizenship or Place of Organization United States of America

Number of Shares Beneficially Owned by Each Reporting Person With			5.		Sole Voting Power 0 shares

			6.		Shared Voting Power 4,535,919 shares (2)

			7.		Sole Dispositive Power 0 shares

			8.		Shared Dispositive Power 4,535,919 shares (2)

	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,535,919 shares (2)

	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o

	11.	Percent of Class Represented by Amount in Row (9) 10.0% (3)

	12.	Type of Reporting Person (See Instructions) IN

(1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(3) This percentage is calculated based upon 45,264,419 shares of Common Stock outstanding as of November 2, 2020 as indicated in the Issuers Form 10-Q filed on November 9, 2020.

Item 1.
	(a)	Name of Issuer Homology Medicines, Inc.
	(b)	Address of Issuers Principal Executive Offices On Patriots Park Bedford, MA 01730

Item 2.
	(a)	Name of Person Filing 5AM Ventures IV, L.P. (Ventures IV) 5AM Co-Investors IV, L.P. (Co-Investors IV) 5AM Partners IV, LLC (Partners IV) Dr. John D. Diekman (Diekman) Andrew J. Schwab (Schwab) Dr. Scott M. Rocklage (Rocklage)
	(b)	Address of Principal Business Office or, if none, Residence c/o 5AM Ventures 501 Second Street, Suite 350 San Francisco, CA 94107
	(c)	Citizenship
		Entities:	5AM Ventures IV, L.P.	- Delaware
			5AM Co-Investors IV, L.P.	- Delaware
			5AM Partners IV, LLC	- Delaware

		Individuals:	Diekman	- United States of America
			Schwab	- United States of America
			Rocklage	- United States of America
	(d)	Title of Class of Securities Common Stock
	(e)	CUSIP Number 438083107

Item 3.	If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

	Not applicable.

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

Reporting Persons	Shares Held Directly	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Beneficial Ownership	Percentage of Class (4)
Ventures IV (1) (3)	4,354,484		4,354,484		4,354,484	4,354,484	9.6	%
Co-Investors IV (2) (3)	181,435		181,435		181,435	181,435	0.4	%
Partners IV (1) (2) (3)			4,535,919		4,535,919	4,535,919	10.0	%
Diekman (1) (2) (3)			4,535,919		4,535,919	4,535,919	10.0	%
Schwab (1) (2) (3)			4,535,919		4,535,919	4,535,919	10.0	%
Rocklage (1) (2) (3)			4,535,919		4,535,919	4,535,919	10.0	%

(1) Includes 4,354,484 shares of Common Stock held by Ventures IV.

(2) Includes 181,435 shares of Common Stock held by Co-Investors IV.

(3) Partners IV serves as the sole general partner of Ventures IV and Co-Investors IV. Diekman, Schwab and Rocklage are managing members of Partners IV and share voting and dispositive power over the shares held by Ventures IV and Co-Investors IV.

(4) This percentage is calculated based upon 45,264,419 shares of Common Stock outstanding as of November 2, 2020 as indicated in the Issuers Form 10-Q filed on November 9, 2020.

Item 5.	Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

Item 6.	Ownership of More than Five Percent on Behalf of Another Person
	Not applicable.

Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
	Not applicable.

Item 8.	Identification and Classification of Members of the Group
	Not applicable.

Item 9.	Notice of Dissolution of Group
	Not applicable.

Item 10.

Certification

Not applicable.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 16, 2021

5AM Ventures IV, L.P.		5AM Co-Investors IV, L.P.

By:	5AM Partners IV, LLC	By:	5AM Partners IV, LLC
its	General Partner	its	General Partner

By:	/s/ Andrew J. Schwab	By:	/s/ Andrew J. Schwab
	Name: Andrew J. Schwab		Name: Andrew J. Schwab
	Title: Managing Member		Title: Managing Member

5AM Partners IV, LLC

By:	/s/ Andrew J. Schwab
	Name: Andrew J. Schwab
	Title: Managing Member


	/s/ Dr. John D. Diekman		/s/ Andrew J. Schwab
	Dr. John D. Diekman		Andrew J. Schwab


	/s/ Dr. Scott M. Rocklage
	Dr. Scott M. Rocklage

	ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

Exhibit(s):

A - Joint Filing Statement

EXHIBIT A

JOINT FILING STATEMENT

We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the

Common Stock of Homology Medicines, Inc. is filed on behalf of each of us.

Dated: February 16, 2021

5AM Ventures IV, L.P.		5AM Co-Investors IV, L.P.

By:	5AM Partners IV, LLC	By:	5AM Partners IV, LLC
its	General Partner	its	General Partner

By:	/s/ Andrew J. Schwab	By:	/s/ Andrew J. Schwab
	Name: Andrew J. Schwab		Name: Andrew J. Schwab
	Title: Managing Member		Title: Managing Member

5AM Partners IV, LLC

By:	/s/ Andrew J. Schwab
	Name: Andrew J. Schwab
	Title: Managing Member


	/s/ Dr. John D. Diekman		/s/ Andrew J. Schwab
	Dr. John D. Diekman		Andrew J. Schwab


	/s/ Dr. Scott M. Rocklage
	Dr. Scott M. Rocklage